wt1-sensitized allogeneic t-lymphocytes
Cell therapyexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 2012 (NCT01758328)
Timeline
2010s
- Jan 1, 2012
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Wilms tumor proteinImmunity, passive
immunity, passive - wt1
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- wt1-sensitized allogeneic t-lymphocytes
- wt1-specific donor-derived t cells
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01640301 | Phase 1/Phase 2 (Phase 2) | Dec 1, 2012 | National Cancer Institute (NCI), University of Washington |
| NCT01758328 | Phase 1 | Dec 1, 2012 | Cornell University |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Cornell University | Academic/Hospital | 1 | 1 | 1 | 2012 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2012 |
| University of Washington | Academic/Hospital | 1 | 1 | 1 | 2012 |
3 organizations
Page 1 / 1